	US 11,945,846 B2
	Stapled intracellular-targeting antimicrobial peptides to treat infection
Loren D. Walensky, Newton, MA (US); and Rida Mourtada, Brookline, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Mar. 9, 2020, as Appl. No. 16/813,528.
Application 16/813,528 is a continuation of application No. 15/445,502, filed on Feb. 28, 2017, abandoned.
Claims priority of provisional application 62/301,426, filed on Feb. 29, 2016.
Prior Publication US 2020/0308236 A1, Oct. 1, 2020
Int. Cl. A61K 38/08 (2019.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/435 (2006.01); C07K 14/46 (2006.01); C07K 14/47 (2006.01)

CPC C07K 14/461 (2013.01) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 38/1703 (2013.01); A61K 38/1706 (2013.01); A61K 38/1709 (2013.01); A61K 38/1767 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/43504 (2013.01); C07K 14/463 (2013.01); C07K 14/47 (2013.01)]

27 Claims

1. A stapled peptide or a pharmaceutically acceptable salt thereof comprising the amino acid sequence TRSSRAGLQWPVGRVX₁RLLX₂K (SEQ ID NO:38), TRSSRAGLQWPX₁GRVX₂RLLRK (SEQ ID NO:42), TRSSRAGLX₁WPVX₂RVHRLLRK (SEQ ID NO:43), TRX₁SRAX₂LQWPVGRVHRLLRK (SEQ ID NO:47), TRSSRAX₃LQWPVGX₄VHRLLRK (SEQ ID NO:55), or TRSSX₃AGLQWPX₄GRVHRLLRK (SEQ ID NO:57),

wherein each of X₁, X₂, X₃, and X₄is a non-natural amino acid,

wherein X₁and X₂are cross-linked to each other where present, and

wherein X₃and X₄are cross-linked to each other where present.